59 related articles for article (PubMed ID: 27916988)
1. Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls.
Heebøll S; Poulsen MK; Ornstrup MJ; Kjær TN; Pedersen SB; Nielsen S; Grønbæk H; Handberg A
Int J Obes (Lond); 2017 Feb; 41(2):262-267. PubMed ID: 27916988
[TBL] [Abstract][Full Text] [Related]
2. Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL).
Mocciaro G; Allison M; Jenkins B; Azzu V; Huang-Doran I; Herrera-Marcos LV; Hall Z; Murgia A; Susan D; Frontini M; Vidal-Puig A; Koulman A; Griffin JL; Vacca M
Mol Metab; 2023 Jul; 73():101728. PubMed ID: 37084865
[TBL] [Abstract][Full Text] [Related]
3. Leukocyte cell-derived chemotaxin 2 correlates with pediatric non-alcoholic fatty liver disease.
Paine-Cabrera D; Harvey LK; Robarts DR; Pritchard MT; Thyfault J; Weinman SA; Apte U; Slowik V
Clin Transl Sci; 2023 Dec; 16(12):2719-2728. PubMed ID: 37877453
[TBL] [Abstract][Full Text] [Related]
4. Glutamate-Serine-Glycine Index: A Novel Potential Biomarker in Pediatric Non-Alcoholic Fatty Liver Disease.
Leonetti S; Herzog RI; Caprio S; Santoro N; Tricò D
Children (Basel); 2020 Dec; 7(12):. PubMed ID: 33291552
[TBL] [Abstract][Full Text] [Related]
5. The polymorphism analysis for CD36 among platelet donors.
Lyu Q; Lin Y; Pan Y; Guan X; Ji X; Peng M; Li Q; Wang Z; Zhang Z; Luo Z; Su P; Wang J
Sci Rep; 2024 Apr; 14(1):8534. PubMed ID: 38609394
[TBL] [Abstract][Full Text] [Related]
6. The Circulating CTRP13 in Type 2 Diabetes and Non-Alcoholic Fatty Liver Patients.
Shanaki M; Fadaei R; Moradi N; Emamgholipour S; Poustchi H
PLoS One; 2016; 11(12):e0168082. PubMed ID: 27936230
[TBL] [Abstract][Full Text] [Related]
7. Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM; Sanyal AJ
Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
[TBL] [Abstract][Full Text] [Related]
8. Obesity/insulin resistance rather than liver fat increases coagulation factor activities and expression in humans.
Lallukka S; Luukkonen PK; Zhou Y; Isokuortti E; Leivonen M; Juuti A; Hakkarainen A; Orho-Melander M; Lundbom N; Olkkonen VM; Lassila R; Yki-Järvinen H
Thromb Haemost; 2017 Jan; 117(2):286-294. PubMed ID: 27929200
[TBL] [Abstract][Full Text] [Related]
9. Hepatic lipid metabolism and non-alcoholic fatty liver disease in aging.
Gong Z; Tas E; Yakar S; Muzumdar R
Mol Cell Endocrinol; 2017 Nov; 455():115-130. PubMed ID: 28017785
[TBL] [Abstract][Full Text] [Related]
10. Amelioration of non-alcoholic fatty liver disease with NPC1L1-targeted IgY or n-3 polyunsaturated fatty acids in mice.
Bae JS; Park JM; Lee J; Oh BC; Jang SH; Lee YB; Han YM; Ock CY; Cha JY; Hahm KB
Metabolism; 2017 Jan; 66():32-44. PubMed ID: 27923447
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic fatty liver disease - A multisystem disease?
Mikolasevic I; Milic S; Turk Wensveen T; Grgic I; Jakopcic I; Stimac D; Wensveen F; Orlic L
World J Gastroenterol; 2016 Nov; 22(43):9488-9505. PubMed ID: 27920470
[TBL] [Abstract][Full Text] [Related]
12. Upregulated absorption of dietary palmitic acids with changes in intestinal transporters in non-alcoholic steatohepatitis (NASH).
Utsunomiya H; Yamamoto Y; Takeshita E; Tokumoto Y; Tada F; Miyake T; Hirooka M; Abe M; Kumagi T; Matsuura B; Ikeda Y; Hiasa Y
J Gastroenterol; 2017 Aug; 52(8):940-954. PubMed ID: 28062946
[TBL] [Abstract][Full Text] [Related]
13. Activation of AMPK by berberine induces hepatic lipid accumulation by upregulation of fatty acid translocase CD36 in mice.
Choi YJ; Lee KY; Jung SH; Kim HS; Shim G; Kim MG; Oh YK; Oh SH; Jun DW; Lee BH
Toxicol Appl Pharmacol; 2017 Feb; 316():74-82. PubMed ID: 28038998
[TBL] [Abstract][Full Text] [Related]
14. Cluster of Differentiation 36 Deficiency Aggravates Macrophage Infiltration and Hepatic Inflammation by Upregulating Monocyte Chemotactic Protein-1 Expression of Hepatocytes Through Histone Deacetylase 2-Dependent Pathway.
Zhong S; Zhao L; Wang Y; Zhang C; Liu J; Wang P; Zhou W; Yang P; Varghese Z; Moorhead JF; Chen Y; Ruan XZ
Antioxid Redox Signal; 2017 Aug; 27(4):201-214. PubMed ID: 27967209
[TBL] [Abstract][Full Text] [Related]
15. Plasma cathepsin D correlates with histological classifications of fatty liver disease in adults and responds to intervention.
Walenbergh SM; Houben T; Rensen SS; Bieghs V; Hendrikx T; van Gorp PJ; Oligschlaeger Y; Jeurissen ML; Gijbels MJ; Buurman WA; Vreugdenhil AC; Greve JW; Plat J; Hofker MH; Kalhan S; Pihlajamäki J; Lindsey P; Koek GH; Shiri-Sverdlov R
Sci Rep; 2016 Dec; 6():38278. PubMed ID: 27922112
[TBL] [Abstract][Full Text] [Related]
16. [Role of CD36 in nonalcoholic fatty liver disease].
Zhan Z; Ren H; Peng ML
Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):953-956. PubMed ID: 29325301
[TBL] [Abstract][Full Text] [Related]
17. The Differential Expression of Cide Family Members is Associated with Nafld Progression from Steatosis to Steatohepatitis.
Sans A; Bonnafous S; Rousseau D; Patouraux S; Canivet CM; Leclere PS; Tran-Van-Nhieu J; Luci C; Bailly-Maitre B; Xu X; Lee AH; Minehira K; Anty R; Tran A; Iannelli A; Gual P
Sci Rep; 2019 May; 9(1):7501. PubMed ID: 31097771
[TBL] [Abstract][Full Text] [Related]
18. Association between gut microbiota and hepatocellular carcinoma from 2011 to 2022: Bibliometric analysis and global trends.
Chen Z; Ding C; Gu Y; He Y; Chen B; Zheng S; Li Q
Front Oncol; 2023; 13():1120515. PubMed ID: 37064156
[TBL] [Abstract][Full Text] [Related]
19. Biological Mechanisms and Related Natural Inhibitors of CD36 in Nonalcoholic Fatty Liver.
Feng Y; Sun W; Sun F; Yin G; Liang P; Chen S; Liu X; Jiang T; Zhang F
Drug Des Devel Ther; 2022; 16():3829-3845. PubMed ID: 36388082
[TBL] [Abstract][Full Text] [Related]
20. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?
Rada P; González-Rodríguez Á; García-Monzón C; Valverde ÁM
Cell Death Dis; 2020 Sep; 11(9):802. PubMed ID: 32978374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
